JP2020530776A5 - - Google Patents

Info

Publication number
JP2020530776A5
JP2020530776A5 JP2020520424A JP2020520424A JP2020530776A5 JP 2020530776 A5 JP2020530776 A5 JP 2020530776A5 JP 2020520424 A JP2020520424 A JP 2020520424A JP 2020520424 A JP2020520424 A JP 2020520424A JP 2020530776 A5 JP2020530776 A5 JP 2020530776A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
percentage homology
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020520424A
Other languages
English (en)
Japanese (ja)
Other versions
JP7383605B2 (ja
JP2020530776A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/039144 external-priority patent/WO2019005634A2/en
Publication of JP2020530776A publication Critical patent/JP2020530776A/ja
Publication of JP2020530776A5 publication Critical patent/JP2020530776A5/ja
Priority to JP2023190606A priority Critical patent/JP7610680B2/ja
Application granted granted Critical
Publication of JP7383605B2 publication Critical patent/JP7383605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020520424A 2017-06-25 2018-06-22 抗pd-l1抗体とその作製及び使用方法 Active JP7383605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023190606A JP7610680B2 (ja) 2017-06-25 2023-11-08 抗pd-l1抗体とその作製及び使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762524553P 2017-06-25 2017-06-25
US62/524,553 2017-06-25
PCT/US2018/039144 WO2019005634A2 (en) 2017-06-25 2018-06-22 ANTI-PD-L1 ANTIBODIES AND METHODS OF PREPARATION AND USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023190606A Division JP7610680B2 (ja) 2017-06-25 2023-11-08 抗pd-l1抗体とその作製及び使用方法

Publications (3)

Publication Number Publication Date
JP2020530776A JP2020530776A (ja) 2020-10-29
JP2020530776A5 true JP2020530776A5 (enExample) 2022-01-17
JP7383605B2 JP7383605B2 (ja) 2023-11-20

Family

ID=64742649

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520424A Active JP7383605B2 (ja) 2017-06-25 2018-06-22 抗pd-l1抗体とその作製及び使用方法
JP2023190606A Active JP7610680B2 (ja) 2017-06-25 2023-11-08 抗pd-l1抗体とその作製及び使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023190606A Active JP7610680B2 (ja) 2017-06-25 2023-11-08 抗pd-l1抗体とその作製及び使用方法

Country Status (5)

Country Link
US (1) US11560431B2 (enExample)
EP (1) EP3645738A4 (enExample)
JP (2) JP7383605B2 (enExample)
CN (2) CN110831972B (enExample)
WO (1) WO2019005634A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202020159A (zh) * 2018-11-16 2020-06-01 大陸商南京金斯瑞生物科技有限公司 人源化抗人pd-l1單克隆抗體及其製備方法和用途
CN109929037B (zh) 2019-04-01 2023-03-17 华博生物医药技术(上海)有限公司 针对程序性死亡配体的结合物及其应用
CN115551894A (zh) 2020-03-12 2022-12-30 以明生物免疫医疗公司 新型抗lilrb4抗体和衍生产物
WO2022171108A1 (zh) * 2021-02-10 2022-08-18 上海济煜医药科技有限公司 抗pd-l1抗体及其用途
US20240294651A1 (en) 2023-01-30 2024-09-05 Kymab Limited Antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MX356367B (es) * 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
BR112014012819B1 (pt) * 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
TWI888366B (zh) * 2013-07-16 2025-07-01 美商建南德克公司 利用pd-1軸結合拮抗劑及tigit抑制劑治療癌症之方法
US20150210772A1 (en) * 2013-12-17 2015-07-30 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
SG11201704056XA (en) * 2014-11-20 2017-06-29 Hoffmann La Roche Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
MX388405B (es) * 2015-05-29 2025-03-19 Genentech Inc Un anticuerpo anti-pd-l1 para usarse en el tratamiento de cáncer en sujetos que tienen nivel medio o bajo de metilación en la región promotora pd-l1.
US11787863B2 (en) * 2017-06-25 2023-10-17 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
EP3703736A4 (en) * 2017-11-02 2021-11-03 Systimmune, Inc. BISPECIFIC ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
EP3773621A4 (en) * 2018-03-27 2022-03-23 Systimmune, Inc. GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE

Similar Documents

Publication Publication Date Title
JP2020529863A5 (enExample)
JP2020529862A5 (enExample)
JP7685095B2 (ja) 多重特異性抗体とその作製及び使用方法
JP2020531043A5 (enExample)
JP7399852B2 (ja) 多重特異性抗体とその作製及び使用方法
AU2022350588A1 (en) Antibody, antibody-drug conjugate thereof and use thereof
JP2024037894A5 (enExample)
IL276830B2 (en) Anti-claudin 18.2 antibodies and uses thereof
WO2021213434A1 (zh) 一种抗Nectin-4的抗体及其应用
JP2023509196A5 (enExample)
JP2022515318A5 (enExample)
JP2021515559A5 (enExample)
JP2021527431A5 (enExample)
JP2022533418A5 (enExample)
CN110869389A (zh) 抗ror1抗体及其制备和使用方法
JP2020501531A5 (enExample)
RU2008135132A (ru) Антитела-антагонисты интерлейкина-17 (ил-17) для лечения рака
FI3452513T3 (fi) Humanisoituja anti-il-1r3-vasta-aineita
RU2017114968A (ru) Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171)
JP2021501575A5 (enExample)
JP2024532886A5 (enExample)
CN110831972B (zh) 抗pd-l1抗体及其制备和使用方法
EP4242231A1 (en) Anti-siglec-15 antibody and application thereof in preparing drug
CN119053607B (zh) 喜树碱类化合物及其偶联物、其制备方法和用途
WO2025087323A1 (zh) B7-h3抗体药物偶联物及其应用